APELLIS PHARMACEUTICALS INC's ticker is and the CUSIP is 03753U906. A total of 6 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,750 | +24.5% | 519,200 | +198.0% | 0.02% | +23.1% |
| Q2 2023 | $15,869 | +35.0% | 174,200 | -2.2% | 0.01% | +30.0% |
| Q1 2023 | $11,754 | +51.0% | 178,200 | +18.4% | 0.01% | +25.0% |
| Q4 2022 | $7,782 | -99.4% | 150,500 | +709.1% | 0.01% | +700.0% |
| Q3 2022 | $1,270,000 | -37.2% | 18,600 | -58.4% | 0.00% | -50.0% |
| Q2 2022 | $2,021,000 | -9.6% | 44,700 | +1.6% | 0.00% | 0.0% |
| Q1 2022 | $2,235,000 | +1485.1% | 44,000 | +1366.7% | 0.00% | – |
| Q4 2021 | $141,000 | -88.0% | 3,000 | -82.8% | 0.00% | -100.0% |
| Q3 2021 | $1,179,000 | +16.6% | 17,400 | +8.8% | 0.00% | 0.0% |
| Q2 2021 | $1,011,000 | +34.8% | 16,000 | +9042.9% | 0.00% | 0.0% |
| Q1 2021 | $750,000 | – | 175 | -62.9% | 0.00% | – |
| Q4 2020 | $0 | – | 472 | +59.5% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 296 | -25.3% | 0.00% | -100.0% |
| Q2 2020 | $1,293,000 | +527.7% | 396 | +414.3% | 0.00% | – |
| Q1 2020 | $206,000 | -77.6% | 77 | -74.4% | 0.00% | -100.0% |
| Q4 2019 | $921,000 | +4285.7% | 301 | +3244.4% | 0.00% | – |
| Q3 2019 | $21,000 | +320.0% | 9 | +350.0% | 0.00% | – |
| Q2 2019 | $5,000 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 300,000 | $9,888,000 | 2.91% |
| PURA VIDA INVESTMENTS, LLC | 259,100 | $8,540,000 | 0.26% |
| GROUP ONE TRADING, L.P. | 92,000 | $3,032,000 | 0.00% |
| SIMPLEX TRADING, LLC | 17,400 | $1,179,000 | 0.00% |
| JPMORGAN CHASE & CO | 113,100 | $3,728,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |